• BridgeBio Pharma CEO Neil Kumar reported sales of 79,226 common shares on June 4-5 at weighted average prices of USD 65.72-68.96.
• Transactions were reported as indirect holdings through the Kumar Haldea Family Irrevocable Trust and Kumar Haldea Revocable Trust.
• Post-transaction holdings totaled 4,318,447 shares in the revocable trust, 515,686 shares in the irrevocable trust, 243,327 shares held directly.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BridgeBio Pharma Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001470831-26-000523), on June 08, 2026, and is solely responsible for the information contained therein.